Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

W. Sikov, D. Berry, C. Perou, et al.. (2015). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 845 times. https://doi.org/10.1200/JCO.2014.57.0572

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)

Erica T. Warner, K. Ballman, C. Strand, et al.. (2016). Breast Cancer Research and Treatment. Cited 51 times. https://doi.org/10.1007/s10549-016-3918-5

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Mehra Golshan, C. Cirrincione, W. Sikov, et al.. (2015). Annals of surgery. Cited 13 times. https://doi.org/10.1097/SLA.0000000000001417

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

D. Ollila, C. Cirrincione, D. Berry, et al.. (2017). Journal of the American College of Surgeons. Cited 9 times. https://doi.org/10.1016/j.jamcollsurg.2016.12.036